Abrocitinib: all 42 studies that test it

Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• Abrocitinib Dose Tapering in Patients With Atopic DermatitisNot yet recruitingNCT07848074Phase 4
• Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of AgeNot yet recruitingNCT07823595Phase 3
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down SyndromeRecruitingNCT07242638Phase 2
• A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe EczemaRecruitingNCT06807281Phase 3
• A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe EczemaRecruitingNCT06807268Phase 3
• Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal NecrolysisRecruitingNCT06119490Early Phase 1
• Janus Kinase Inhibition in Granuloma AnnulareCompletedNCT05650736Phase 2Results posted
• A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in IndiaCompletedNCT05375929Phase 3Results posted
• A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy ParticipantsCompletedNCT05067439Phase 1Results posted
• Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown OriginCompletedNCT05038982Phase 2Results posted
• A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.CompletedNCT04903093Phase 1Results posted
• Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT04345367Phase 3Results posted
• Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic DermatitisCompletedNCT03915496Phase 2Results posted
• JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic DermatitisCompletedNCT03796676Phase 3Results posted
• Study of PF 04965842 Effect on MATE1/2K Activity in Healthy ParticipantsCompletedNCT03796182Phase 1Results posted
• Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT03720470Phase 3Results posted
• A Renal Impairment Study for PF-04965842CompletedNCT03660241Phase 1Results posted
• Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring SubjectsCompletedNCT03627767Phase 3Results posted
• A Hepatic Impairment Study for PF-04965842.CompletedNCT03626415Phase 1Results posted
• Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisCompletedNCT03575871Phase 3Results posted
• Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic DermatitisCompletedNCT03349060Phase 3Results posted
• Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic DermatitisCompletedNCT02780167Phase 2Results posted
• Study to Evaluate PF-04965842 in Patients With Moderate to Severe PsoriasisTerminatedNCT02201524Phase 2Results posted
• Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVIDActive, not recruitingNCT06597396Phase 2
• Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid TherapyCompletedNCT06283550Phase 2
• Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)Active, not recruitingNCT05743244Phase 2
• Janus Kinase Inhibition in SarcoidosisCompletedNCT05696795Phase 2
• Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With DupilumabCompletedNCT05602207Phase 4
• JAK Inhibition in Food AllergyCompletedNCT05069831Phase 1
• Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy ParticipantsCompletedNCT04099563Phase 1
• Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy ParticipantsCompletedNCT03806101Phase 1
• Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy ParticipantsCompletedNCT03742336Phase 1
• A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female SubjectsCompletedNCT03662516Phase 1
• A Study to Determine the Effects of PF-04965842 on Midazolam PK in Healthy VolunteersCompletedNCT03647670Phase 1
• Drug Interaction Study Evaluating the Effect of Rifampin on PK and Safety of PF 04965842.CompletedNCT03637790Phase 1
• Drug Drug Interaction Study Evaluating the Effect of Fluvoxamine or Fluconazole on PK and Safety of PF-04965842.CompletedNCT03634345Phase 1
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisCompletedNCT03422822Phase 3
• A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and MoxifloxacinCompletedNCT03386279Phase 1
• Absorption, Metabolism, Excretion and Absolute BioavailabilityCompletedNCT03250039Phase 1
• AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy SubjectsCompletedNCT02163161Phase 1
• First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese SubjectsCompletedNCT01835197Phase 1

← Abrocitinib overview